BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24948702)

  • 1. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
    Pagano L; Verga L; Busca A; Martino B; Mitra ME; Fanci R; Ballanti S; Picardi M; Castagnola C; Cattaneo C; Nadali G; Nosari A; Candoni A; Caira M; Salutari P; Lessi F; Aversa F; Tumbarello M
    J Antimicrob Chemother; 2014 Nov; 69(11):3142-7. PubMed ID: 24948702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
    Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
    Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
    Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
    Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
    Cattaneo C; Panzali A; Passi A; Borlenghi E; Lamorgese C; Petullà M; Re A; Caimi L; Rossi G
    Mycoses; 2015 Jun; 58(6):362-7. PubMed ID: 25907298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
    Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
    Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
    Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
    Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
    Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
    PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia.
    Hahn-Ast C; Felder L; Mayer K; Mückter S; Ruhnke M; Hein R; Hellmich M; Schwab K; Rachow T; Brossart P; von Lilienfeld-Toal M
    Ann Hematol; 2016 May; 95(6):1001-9. PubMed ID: 27021301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
    Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
    J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.